DOP2023000170A - Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida - Google Patents

Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida

Info

Publication number
DOP2023000170A
DOP2023000170A DO2023000170A DO2023000170A DOP2023000170A DO P2023000170 A DOP2023000170 A DO P2023000170A DO 2023000170 A DO2023000170 A DO 2023000170A DO 2023000170 A DO2023000170 A DO 2023000170A DO P2023000170 A DOP2023000170 A DO P2023000170A
Authority
DO
Dominican Republic
Prior art keywords
5dioxo14
32h6aza3
pyridine1
trifluoromethyl
triazola2
Prior art date
Application number
DO2023000170A
Other languages
English (en)
Inventor
Röhrig Susanne
Levilain Guillaume
Olenik Britta
Jacobs Tia
Rubino Franco
Sowa Michal
Ziem Krischan
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DOP2023000170A publication Critical patent/DOP2023000170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas de (4S)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida que son la modificación cristalina I y la modificación cristalina II, a procesos para su preparación, a composiciones farmacéuticas que las comprenden y a su uso en el control de trastornos.
DO2023000170A 2021-03-09 2023-08-29 Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida DOP2023000170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21161489 2021-03-09
PCT/EP2022/055521 WO2022189279A1 (en) 2021-03-09 2022-03-04 Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide

Publications (1)

Publication Number Publication Date
DOP2023000170A true DOP2023000170A (es) 2023-09-29

Family

ID=74867465

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000170A DOP2023000170A (es) 2021-03-09 2023-08-29 Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida

Country Status (15)

Country Link
US (1) US20240174633A1 (es)
EP (1) EP4304714A1 (es)
JP (1) JP2024508971A (es)
KR (1) KR20230155505A (es)
CN (1) CN117015535A (es)
AU (1) AU2022235150A1 (es)
BR (1) BR112023016298A2 (es)
CA (1) CA3212645A1 (es)
CL (1) CL2023002676A1 (es)
CO (1) CO2023011801A2 (es)
DO (1) DOP2023000170A (es)
IL (1) IL305231A (es)
MX (1) MX2023010614A (es)
TW (1) TW202302561A (es)
WO (1) WO2022189279A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283464B1 (en) 2015-04-16 2019-10-23 Merck Sharp & Dohme Corp. Factor xia inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
PT3765452T (pt) 2018-03-15 2022-06-23 Bayer Pharma AG Processo preparativo de dois derivados de 4-{[(2s)-2-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
JOP20210161A1 (ar) 2018-12-21 2023-01-30 Bayer Ag مشتقات أكسوبيريدين تحمل بدائل

Also Published As

Publication number Publication date
TW202302561A (zh) 2023-01-16
BR112023016298A2 (pt) 2023-10-03
CL2023002676A1 (es) 2024-02-09
KR20230155505A (ko) 2023-11-10
IL305231A (en) 2023-10-01
EP4304714A1 (en) 2024-01-17
CA3212645A1 (en) 2022-09-15
CN117015535A (zh) 2023-11-07
WO2022189279A1 (en) 2022-09-15
US20240174633A1 (en) 2024-05-30
AU2022235150A1 (en) 2023-08-31
CO2023011801A2 (es) 2023-09-18
JP2024508971A (ja) 2024-02-28
MX2023010614A (es) 2023-09-19

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2021000387A1 (es) Compuestos de anillo fusionado
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
EA202090890A1 (ru) Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
ECSP19072294A (es) Composición farmacéutica que comprende selexipag
DOP2023000170A (es) Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
NI201800111A (es) Formas cristalinas de n-[2-3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6- (trifluorometil)-piridin-2-carboxamida.
CO2021007908A2 (es) Derivados de oxopiridina sustituidos
CL2021000930A1 (es) Piridazinas novedosas
ECSP20008441A (es) Dihidrooxadiazinonas
CO2017007249A2 (es) Modificación cristalina de propanil
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2023001220A1 (es) Inhibidores de interleucina-17
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
MX2020004214A (es) Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona.
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
AR112841A1 (es) Composiciones y procedimientos para mejorar el uso de nitrógeno en un rumiante
AR123685A1 (es) Antagonistas del mrgx2
CL2019000118A1 (es) Composiciones de l-triptófano y uso de las mismas.
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
AR117132A1 (es) Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas